NON-CME SymposiA

Ongoing Research of an Investigational Inhaled Prostanoid Prodrug in Pulmonary Vascular and Fibrotic Lung Diseases

Sheraton Phoenix Downtown: 340 N 3rd Street, Phoenix, AZ, 85004, Phoenix Ballroom C
Sponsored by Insmed Incorporated.

---

Program Description

Follow the science that’s shaping what comes next in pulmonary vascular and fibrotic lung diseases.

Join us for a dynamic, forward-looking dinner symposium exploring the evolving science of pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD), idiopathic pulmonary fibrosis (IPF), and progressive pulmonary fibrosis (PPF). These conditions continue to challenge clinicians and researchers and raise compelling questions about disease biology, progression, and the future direction of clinical research. Expert speakers will connect the disease landscape with the scientific thinking driving a development program.

At the center of the conversation will be an investigational inhaled prostanoid prodrug currently being studied across all 4 disease states. The discussion will move beyond the fundamentals to examine emerging evidence, persistent uncertainties, and the research priorities shaping the next generation of clinical questions. Speakers will unpack the program’s scientific rationale, explain how current and prior research informed its direction, and highlight the considerations guiding investigation.

Attendees will take a closer look at the ongoing Phase 3 trial designs, including the patient populations under study and the key questions the trials are designed to address. By connecting disease biology, research insights, and clinical trial strategy, the symposium will offer a compelling look at how a broad development program advances from scientific hypothesis to Phase 3 investigation. Expect a lively, thought-provoking dialogue that explores the opportunities, challenges, and unanswered questions moving the field forward. Gain a deeper perspective on the science and strategy helping define what may come next for PAH, PH-ILD, IPF, and PPF.

This is a non-CME event and does not qualify for CME or CE, or MOC credit. This event is not part of the official CHEST Annual Meeting 2026 conference sessions. This event is not an endorsement by CHEST and does not reflect the views or opinions of CHEST.

Presenters

Jean M. Elwing, MD, FCCP
University of Cincinnati
Professor of Medicine
Director, Pulmonary Hypertension Program; Pulmonary Hypertension Association Certified Center (PHCCC); Pulmonary, Critical Care and Sleep Medicine
Cincinnati, OH

Mridu Gulati, MD, MPH
Yale School of Medicine
Associate Director of the Yale Interstitial Lung Disease Program; Associate Professor of Medicine (Pulmonary, Critical Care, and Sleep Medicine)
New Haven, CT

The speakers are being compensated by Insmed.